FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
about
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selectionFibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implicationsGenomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumorsFunctional roles of fibroblast growth factor receptors (FGFRs) signaling in human cancersFGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancerPrognostic value of FGFR gene amplification in patients with different types of cancer: a systematic review and meta-analysis.Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutationsFGFR1 is an adverse outcome indicator for luminal A breast cancers.Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumorsAn integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomasInferring pathway dysregulation in cancers from multiple types of omic data.The Role of FGFR1 Gene Amplification as a Poor Prognostic Factor in Squamous Cell Lung Cancer: A Meta-Analysis of Published DataAnalysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.A Versatile Tumor Gene Deletion System Reveals a Crucial Role for FGFR1 in Breast Cancer Metastasis.Mammary gland growth factors: roles in normal development and in cancer.Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinomaKinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLCOptical fiber-based in vivo quantification of growth factor receptors.Treatment options for patients with triple-negative breast cancerDifferential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growthThe FGF/FGFR axis as a therapeutic target in breast cancer.Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy.Rationale for targeting fibroblast growth factor receptor signaling in breast cancerFibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma.Multiple gene aberrations and breast cancer: lessons from super-responders.Mammary tumorigenesis induced by fibroblast growth factor receptor 1 requires activation of the epidermal growth factor receptor.Genetic characterization of breast cancer and implications for clinical managementMutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer.FGFR1 cleavage and nuclear translocation regulates breast cancer cell behavior.Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitorsFibroblast growth factor family aberrations in cancers: clinical and molecular characteristicsGene fusions associated with recurrent amplicons represent a class of passenger aberrations in breast cancerChallenges and opportunities in the targeting of fibroblast growth factor receptors in breast cancer.Characterization of PAR1 and FGFR1 expression in invasive breast carcinomas: Prognostic significance.FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Fibroblast growth factor receptor-1 protein expression is associated with prognosis in estrogen receptor-positive/human epidermal growth factor receptor-2-negative primary breast cancer.Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models.FGFR1 is amplified during the progression of in situ to invasive breast carcinomaDiscordant cellular response to presurgical letrozole in bilateral synchronous ER+ breast cancers with a KRAS mutation or FGFR1 gene amplification.Inhibition of Metastatic Potential in Breast Carcinoma In Vivo and In Vitro through Targeting VEGFRs and FGFRs.
P2860
Q24605762-00FAE537-F487-4714-8A67-D0DA08DA3B72Q26801718-4A0CDA1E-3266-4FDD-B4D2-9103144B2F83Q26998790-7231E6F7-3F33-4ED4-ADCD-411C48FB3944Q26998955-B285471B-B592-45FC-ACDC-A9AEE1E66959Q27851554-5F66C197-0D04-43AA-A140-459A44716D08Q27853061-05052A82-EFD5-47CE-9E61-500ACD058E4BQ27853244-85F9CF76-0AB5-4918-A04F-75D82AD1ECB0Q27853294-2E1CF99E-CE4F-4D03-83FF-10370F5DEF39Q28247372-A3108232-5E9B-4249-B99A-53B3991A212CQ28487526-BE88E2E9-2D72-41A9-A783-74FD33B2F978Q30980125-ECEF8657-774E-400E-ACF1-B2798B7C960AQ31038314-FC5BA34D-CB3C-402C-9A76-39BBC2AD06ADQ33273364-3DA229DF-D001-449D-B688-9222B60B1CA3Q33595554-845A41B4-87BE-4B3F-A0B3-F99964A537FCQ34014659-B971B105-CB3A-491D-A461-40DB1B471BA0Q34064466-8C3EF926-B19A-49BB-B3C4-11CAB0090F1EQ34135320-43436575-71DE-487A-8B88-413BA5522B83Q34226408-6F51865B-6A5C-425B-8A92-41DC1B184B31Q34331406-EED53D7A-97CA-4834-9DDA-02D1E7488EA0Q34490810-A4B17597-83C1-4B53-A5BD-45FC2A5F65B3Q34495216-A87E4654-D589-495D-AC62-0DE743D1D6DEQ35000497-F1406E48-6D23-4B92-AA5B-EB58B500B3FCQ35131258-A1E9647D-0FD0-41B7-88DC-A49FA69461ECQ35273802-CFE7E528-506C-40AA-AA12-5B447977F5E4Q35645466-AC53C5D9-B27B-41F5-AF95-7EEB5417F34BQ35784682-868E3EC4-46BB-4EC7-8490-48994ED9BC90Q35832016-7B926295-6CFC-4DCD-982D-A22FB3D1D8EEQ35861503-D7C2F0FB-8D54-44E2-8C25-3F8F8F6AC1E5Q36027395-0D5D62EB-DBE5-42FF-9A49-7C1BC9B72234Q36094586-7A0513FF-AFD4-4E26-A494-57EE84863032Q36189141-7B00CE93-4B9D-43B8-BCB5-E5F46E4A53AEQ36200413-68DC3476-BF54-4B6C-A0E2-0E004C14AF91Q36245320-05C17E81-28FE-4991-AF02-F8EB9A7F15C1Q36423991-AF5A6F3B-72CF-4ECF-AD80-2FBC08907782Q36524946-C92EC3F6-F0B8-4FC6-80FA-B22CD1970DE8Q36801189-A8E88112-FA67-4A48-97DA-92AF967DECD7Q36903398-59DEA683-D631-4991-B5B9-395D2022CB6DQ36924421-2E43B939-E591-4884-837B-F02FECDCDE39Q36929331-ED312297-9EDC-41F4-825A-F9F34BD9F24CQ36938939-0BE8BCFF-3B18-4CB4-9607-62E8DCB9BA3C
P2860
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@ast
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@en
type
label
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@ast
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@en
prefLabel
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@ast
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@en
P2093
P2860
P50
P356
P1476
FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis.
@en
P2093
Maryou B K Lambros
Nicholas C Turner
Somaia Elbauomy Elsheikh
P2860
P2888
P356
10.1186/BCR1665
P577
2007-01-01T00:00:00Z
P5875
P6179
1014525355